Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation

Klaver, Martijn N; Wintgens, Lisette I S; Wijffels, Maurits C.E.F.; Balt, Jippe C.; Dijk, Vincent F. van; Alipour, Arash; Chaldoupi, S. M.; Derksen, R. H. W. M.; Boersma, Lucas V.A.

doi:10.1007/s10840-020-00728-8

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published large registry of 1,017 patients, reported that PVI was successfully achieved in 95-99% of paroxysmal, persistent and long-standing AF patients. Procedure times were reduced, and safety was maintained (38). Additional phased array products (Medtronic Inc., Minneapolis, MN, USA) include the Multi-Array Septal Catheter (MASC) and the Multi-Array Ablation Catheter (MAAC) which are designed to facilitate elimination of non-pulmonary vein triggers and arrhythmogenic substrates in the atria (38).…”

Section: Ablation Modalities: Comparative E Cacy and New Techniquesmentioning

confidence: 99%

“…Procedure times were reduced, and safety was maintained (38). Additional phased array products (Medtronic Inc., Minneapolis, MN, USA) include the Multi-Array Septal Catheter (MASC) and the Multi-Array Ablation Catheter (MAAC) which are designed to facilitate elimination of non-pulmonary vein triggers and arrhythmogenic substrates in the atria (38). Pending additional investigation none of these products have received approval from the U.S. Food and Drug Administration (FDA).…”

Section: Ablation Modalities: Comparative E Cacy and New Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2

Trohman

Huang

Sharma

2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, once thought to be benign as long as the ventricular rate was controlled, is associated with significant cardiac morbidity and mortality. Increasing life expectancy driven by improved health care and decreased fertility rates has, in most of the world, resulted in the population aged ≥65 years growing more rapidly than the overall population. As the population ages, projections suggest that the burden of AF may increase more than 60% by 2050. Although considerable progress has been made in the treatment and management of AF, primary prevention, secondary prevention, and prevention of thromboembolic complications remain a work in progress. This narrative review was facilitated by a search of MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and other clinically relevant studies. The search was limited to English-language reports published between 1950 and 2021. Atrial fibrillation was searched using the terms primary prevention, hyperthyroidism, Wolff-Parkinson-White syndrome, catheter ablation, surgical ablation, hybrid ablation, stroke prevention, anticoagulation, left atrial occlusion and atrial excision. Google and Google scholar as well as bibliographies of identified articles were reviewed for additional references. In these two manuscripts, we discuss the current strategies available to prevent AF, then compare non-invasive and invasive treatment strategies to diminish AF recurrence. In addition, we examine the pharmacological, percutaneous device and surgical approaches to prevent stroke as well as other types of thromboembolic events.

show abstract

Section: Ablation Modalities: Comparative E Cacy and New Techniquesmentioning

confidence: 99%

Section: Ablation Modalities: Comparative E Cacy and New Techniquesmentioning

confidence: 99%

Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2

Trohman

Huang

Sharma

2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Simultaneously, it can map the pulmonary vein potentials, deliver diagnostic pacing stimuli, and verify the pulmonary vein post-treatment electrical isolation. It seems to allow for successful circumferential ablation of the pulmonary veins while reducing procedure times for patients with paroxysmal/persistent AF 58 .…”

Section: Radiofrequency Ablation-based Cathetersmentioning

confidence: 99%

Bipolar biparietal bidirectional application of radiofrequency in experimental in vitro/in vivo environment

Matteucci¹

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: long-term outcomes in a multicentre clinical study

Martin

Fowler

Brešković

et al. 2022

J Interv Card Electrophysiol

View full text Add to dashboard Cite

Background Recently, a novel cryoballoon ablation catheter has demonstrated acute safety and efficacy in de novo pulmonary vein isolation (PVI) procedures in patients with paroxysmal atrial fibrillation (PAF). However, there are limited studies demonstrating the long-term efficacy. The aim of this study was to evaluate the long-term safety and efficacy of this novel cryoballoon in treating PAF. Methods This was a non-randomized, prospective, multicentre study enrolling 58 consecutive patients. Cryoablation was delivered for 180 s if time to isolation was ≤ 60 s. Otherwise a 240-s cryoablation was performed. One centre performed pre- and post-ablation high-density mapping (n = 9) to characterize lesion formation. After a 3-month blanking period, recurrence was defined as having any documented, symptomatic episode(s) of AF or atrial tachycardia. All patients were followed for 1 year. Results Acute PVI was achieved in 230 of 231 pulmonary veins (99.6%) with 5.3 ± 1.6 cryoablations per patient (1.3 ± 0.7 cryoablations per vein). Forty-three (77%) patients remained arrhythmia-free at 1-year follow-up. Four patients (6.9%) experienced phrenic nerve injury (3 resolved during the index procedure; 1 resolved at 6 months). One serious adverse device event was reported: femoral arterial embolism event occurring 2 weeks post-index procedure. For patients who underwent high-density mapping, cryoablation was antral with 50% of the posterior wall ablated. Conclusions Initial multicentre clinical experience with a novel cryoballoon has demonstrated safety and efficacy of PVI in patients with PAF. Ablation with this cryoballoon provides a wide, antral lesion set with significant debulking of the posterior wall of the left atrium.

show abstract

Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation

Cited by 6 publications

References 21 publications

Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2

Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2

Bipolar biparietal bidirectional application of radiofrequency in experimental in vitro/in vivo environment

Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: long-term outcomes in a multicentre clinical study

Contact Info

Product

Resources

About